Bettina Baessler1,2, Tim Nestler3, Daniel Pinto Dos Santos4, Pia Paffenholz3, Vikram Zeuch5, David Pfister3, David Maintz4, Axel Heidenreich3. 1. Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Cologne, Germany. bettina.baessler@usz.ch. 2. Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland. bettina.baessler@usz.ch. 3. Department of Urology, University Hospital of Cologne, Cologne, Germany. 4. Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Cologne, Germany. 5. Department of Urology, University Hospital of Aachen, Aachen, Germany.
Abstract
OBJECTIVES: To evaluate whether a computed tomography (CT) radiomics-based machine learning classifier can predict histopathology of lymph nodes (LNs) after post-chemotherapy LN dissection (pcRPLND) in patients with metastatic non-seminomatous testicular germ cell tumors (NSTGCTs). METHODS: Eighty patients with retroperitoneal LN metastases and contrast-enhanced CT were included into this retrospective study. Resected LNs were histopathologically classified into "benign" (necrosis/fibrosis) or "malignant" (viable tumor/teratoma). On CT imaging, 204 corresponding LNs were segmented and 97 radiomic features per LN were extracted after standardized image processing. The dataset was split into training, test, and validation sets. After stepwise feature reduction based on reproducibility, variable importance, and correlation analyses, a gradient-boosted tree was trained and tuned on the selected most important features using the training and test datasets. Model validation was performed on the independent validation dataset. RESULTS: The trained machine learning classifier achieved a classification accuracy of 0.81 in the validation dataset with a misclassification of 8 of 36 benign LNs as malignant and 4 of 25 malignant LNs as benign (sensitivity 88%, specificity 72%, negative predictive value 88%). In contrast, a model containing only the LN volume resulted in a classification accuracy of 0.68 with 64% sensitivity and 68% specificity. CONCLUSIONS: CT radiomics represents an exciting new tool for improved prediction of the presence of malignant histopathology in retroperitoneal LN metastases from NSTGCTs, aiming at reducing overtreatment in this group of young patients. Thus, the presented approach should be combined with established clinical biomarkers and further validated in larger, prospective clinical trials. KEY POINTS: • Patients with metastatic non-seminomatous testicular germ cell tumors undergoing post-chemotherapy retroperitoneal lymph node dissection of residual lesions show overtreatment in up to 50%. • We assessed whether a CT radiomics-based machine learning classifier can predict histopathology of lymph nodes after post-chemotherapy lymph node dissection. • The trained machine learning classifier achieved a classification accuracy of 0.81 in the validation dataset with a sensitivity of 88% and a specificity of 78%, thus allowing for prediction of the presence of viable tumor or teratoma in retroperitoneal lymph node metastases.
OBJECTIVES: To evaluate whether a computed tomography (CT) radiomics-based machine learning classifier can predict histopathology of lymph nodes (LNs) after post-chemotherapy LN dissection (pcRPLND) in patients with metastatic non-seminomatous testicular germ cell tumors (NSTGCTs). METHODS: Eighty patients with retroperitoneal LN metastases and contrast-enhanced CT were included into this retrospective study. Resected LNs were histopathologically classified into "benign" (necrosis/fibrosis) or "malignant" (viable tumor/teratoma). On CT imaging, 204 corresponding LNs were segmented and 97 radiomic features per LN were extracted after standardized image processing. The dataset was split into training, test, and validation sets. After stepwise feature reduction based on reproducibility, variable importance, and correlation analyses, a gradient-boosted tree was trained and tuned on the selected most important features using the training and test datasets. Model validation was performed on the independent validation dataset. RESULTS: The trained machine learning classifier achieved a classification accuracy of 0.81 in the validation dataset with a misclassification of 8 of 36 benign LNs as malignant and 4 of 25 malignant LNs as benign (sensitivity 88%, specificity 72%, negative predictive value 88%). In contrast, a model containing only the LN volume resulted in a classification accuracy of 0.68 with 64% sensitivity and 68% specificity. CONCLUSIONS: CT radiomics represents an exciting new tool for improved prediction of the presence of malignant histopathology in retroperitoneal LN metastases from NSTGCTs, aiming at reducing overtreatment in this group of young patients. Thus, the presented approach should be combined with established clinical biomarkers and further validated in larger, prospective clinical trials. KEY POINTS: • Patients with metastatic non-seminomatous testicular germ cell tumors undergoing post-chemotherapy retroperitoneal lymph node dissection of residual lesions show overtreatment in up to 50%. • We assessed whether a CT radiomics-based machine learning classifier can predict histopathology of lymph nodes after post-chemotherapy lymph node dissection. • The trained machine learning classifier achieved a classification accuracy of 0.81 in the validation dataset with a sensitivity of 88% and a specificity of 78%, thus allowing for prediction of the presence of viable tumor or teratoma in retroperitoneal lymph node metastases.
Authors: Ricardo Leão; Madhur Nayan; Nahid Punjani; Michael A S Jewett; Kamel Fadaak; Juan Garisto; Jeremy Lewin; Eshetu G Atenafu; Joan Sweet; Lynn Anson-Cartwright; Peter Boström; Peter Chung; Padraig Warde; Philippe L Bedard; Aditya Bagrodia; Yuval Freifeld; Nicholas Power; Eric Winquist; Robert J Hamilton Journal: Eur Urol Focus Date: 2018-02-07
Authors: O Klepp; P Flodgren; H Maartman-Moe; C E Lindholm; B Unsgaard; H Teigum; S D Fosså; E Paus Journal: Ann Oncol Date: 1990-07 Impact factor: 32.976
Authors: Joost J M van Griethuysen; Andriy Fedorov; Chintan Parmar; Ahmed Hosny; Nicole Aucoin; Vivek Narayan; Regina G H Beets-Tan; Jean-Christophe Fillion-Robin; Steve Pieper; Hugo J W L Aerts Journal: Cancer Res Date: 2017-11-01 Impact factor: 12.701
Authors: Alessandro Nini; Matthias Boschheidgen; Andreas Hiester; Christian Winter; Gerald Antoch; Lars Schimmöller; Peter Albers Journal: World J Urol Date: 2021-11-03 Impact factor: 4.226
Authors: Friedemann Zengerling; Dirk Beyersdorff; Jonas Busch; Julia Heinzelbecker; David Pfister; Christian Ruf; Christian Winter; Peter Albers; Sabine Kliesch; Stefanie Schmidt Journal: World J Urol Date: 2022-07-29 Impact factor: 3.661
Authors: Kathryn E Keenan; Jana G Delfino; Kalina V Jordanova; Megan E Poorman; Prathyush Chirra; Akshay S Chaudhari; Bettina Baessler; Jessica Winfield; Satish E Viswanath; Nandita M deSouza Journal: Med Phys Date: 2021-09-29 Impact factor: 4.506
Authors: Andrew B Chen; Taseen Haque; Sidney Roberts; Sirisha Rambhatla; Giovanni Cacciamani; Prokar Dasgupta; Andrew J Hung Journal: Urol Clin North Am Date: 2021-10-23 Impact factor: 2.766
Authors: Lara Kremer; Melanie von Brandenstein; Maike Wittersheim; Barbara Koeditz; Pia Paffenholz; Martin Hellmich; David Pfister; Axel Heidenreich; Tim Nestler Journal: Transl Androl Urol Date: 2021-04
Authors: Elisabeth Sartoretti; Thomas Sartoretti; Michael Wyss; Carolin Reischauer; Luuk van Smoorenburg; Christoph A Binkert; Sabine Sartoretti-Schefer; Manoj Mannil Journal: Sci Rep Date: 2021-03-09 Impact factor: 4.379